Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer

Affiliations

¹ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
² Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
³ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at.

Comment

Keiichiro Mori et al. Eur Urol. 2021 Mar.

. 2021 Mar;79(3):430-431.

doi: 10.1016/j.eururo.2020.11.034. Epub 2020 Dec 21.

¹ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
² Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
³ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at.

No abstract available

Comment on

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.